Phospho-Chk2 (Thr68)抗体;Phospho-Chk2 (Thr68) Antibody—艾普蒂

+ +

•  

   

     Western blot analysis of Phospho-Chk2(Thr68) in Jurkat treated with UV lysates using Phospho- Chk2 (Thr68) antibody.    

  
  

Phospho-Chk2 (Thr68) antibody is a specialized tool used to detect the activated form of checkpoint kinase 2 (Chk2), a key regulator of the DNA damage response (DDR) pathway. Chk2 is a serine/threonine kinase activated primarily in response to DNA double-strand breaks (DSBs) or replication stress. Its phosphorylation at Thr68. located in the N-terminal SQ/TQ cluster domain, serves as a critical marker of activation. This phosphorylation event is mediated by the upstream kinase ATM (ataxia-telangiectasia mutated), which is recruited to sites of DNA damage. Once phosphorylated, Chk2 undergoes a conformational change, leading to dimer dissociation, autophosphorylation, and full kinase activation. Activated Chk2 then phosphorylates downstream targets, such as p53. CDC25. and BRCA1. to enforce cell cycle arrest, DNA repair, or apoptosis, thereby maintaining genomic stability.

The Phospho-Chk2 (Thr68) antibody is widely used in research to study DDR mechanisms, cancer biology, and therapeutic responses. Its specificity allows scientists to assess Chk2 activation status in cells or tissues exposed to genotoxic agents (e.g., ionizing radiation, chemotherapeutics) or in models of genetic instability. Dysregulation of Chk2 signaling is linked to tumorigenesis, as mutations or altered expression can impair checkpoint control, promoting uncontrolled proliferation. This antibody is essential for elucidating how Chk2 contributes to cancer progression, treatment resistance, and as a potential biomarker for DDR-targeted therapies. Validation methods, including knockout controls or phosphatase treatment, are recommended to confirm signal specificity in experimental setups.